Creso enters the growing CBD market in sport and recreation
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Today, Creso Pharma Limited (ASX:CPH, FRA:1X8) announced a Letter of Interest (LOI) which marks its entry into the CBD market for sport and recreation; an industry whose global valuation is estimated at US$22BN by 2022 and C$220M in Canada alone.
The non-binding LOI has been signed between Creso Pharma Limited and ImpACTIVE Holdings Ltd to distribute Creso’s suite of hemp CBD based human health products, CannaDOL and cannaQIX®, in Canada and the US.
As part of the LOI, Creso will also obtain the rights to distribute ImpACTIVE’s CBD roller application in Switzerland and Europe.
About ImpACTIVE
ImpACTIVE is a Canadian company which has developed a range of CBD based products, designed to reduce muscle and joint inflammation without the use of heavy narcotics or prescriptions pharmaceuticals.
The company was founded by current and former high-profile athletes who have struggled with injury and wanted to provide an alternative treatment route to the athletic community, and its products are promoted by several well-known brand ambassadors.
Distribution across North America and Switzerland
Alongside the North American rollout, Creso will also become an authorised distributor of ImpACTIVE’s CBD based roll on product range, with the initial launch in Switzerland expected to commence April 2021.
The growing sports and recreational market will be Creso’s initial focus. Creso has access to over 2,100 pharmacies and 400 sport and fitness centres in Switzerland and expects to receive strong uptake.
Each distributing party is responsible for obtaining all the necessary regulatory approvals and registrations required to sell the hemp CBD based products in the relevant jurisdiction.
Creso’s Commercial Director Jorge Wernli, commented, “We are very proud to enter the sports and recreational market with such a high calibre partner as ImpACTIVE. This LOI is important for Creso Pharma, as it further broadens our international footprint and provides another large market opportunity.
“We look forward to working with ImpACTIVE to ensure all products are well received in Europe and North America, and also leveraging their innovative product range to further add to the Company’s growing sales profile.”
The launch of cannaDOL will be supported by high profile influencer and two-time WFF World Vice Champion Jenny Dietschweiler, who added: “cannaDOL brings substantial fast relief to joints and the muscles after intensive training. It enables faster high-performance and re-achievement. cannaDOL is really the way to enhance mobility”.
Terms of the Agreement
Under the agreement, the parties have agreed to enter into a formal commercial agreement on or before 1 April 2021 setting out the terms upon which ImpACTIVE will distribute Creso Pharma’s cannaDOL and cannaQIX® products through its established sales channels in Canada and the USA.
The initial term of the agreement is one year and will automatically renew after one year, unless either party notifies the other of their decision to not renew the agreement within 90 days prior to the expiry of the Initial or Renewal Term. Initial Term and Renewal Terms are subject to termination for cause upon notice by either party, or upon failure to meet the above referenced renewal conditions.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
